Research programme: tuberculosis peptide vaccine - EpiVax/Sequella/Valneva
Alternative Names: Peptide TB vaccine - Sequella; TB peptide vaccine - SequellaLatest Information Update: 02 Jul 2013
At a glance
- Originator EpiVax; Intercell; Sequella
- Developer Sequella
- Class Antituberculars; Peptide vaccines; Peptides; Tuberculosis vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Tuberculosis
Most Recent Events
- 02 Jul 2013 No development reported - Preclinical for Tuberculosis in USA (unspecified route)
- 28 May 2013 Intercell has merged with Vivalis to form Valneva
- 24 Oct 2001 Preclinical development for Tuberculosis in USA (Unknown route)